SecBot SecBot
6-K ·Filed Jun 1, 2026

KMDA

KAMADA LTD
BULLISH
Impact 5/10
Horizonmonths Processed5mo ago SEC0001213900-26-063140
Notable filing: 6-K
Actionable Insight ▲ Bullish

The FDA approval of an in-house RFFIT lab is a modest positive for Kamada's rabies franchise, potentially improving margins and reducing supply chain risk. Monitor for any future guidance updates or margin improvements in upcoming quarterly reports.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.70
T+0 close · Jun 1, 2026 · via day close
Latest settled
+12.08%
T+60 · $8.63
Vs SPY
+10.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $7.70entry
  2. T+1 · 6mo ago −2.47%α −2.61% · $7.51
  3. T+5 · 5mo ago −6.88%α −4.13% · $7.17
  4. T+20 · 5mo ago −4.68%α −3.38% · $7.34
  5. T+60 · 3mo ago +12.08%α +10.85% · $8.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufacturing of KEDRAB and KAMRAB. The lab is expected to improve operational efficiencies and reduce reliance on external testing for its leading rabies franchise, which generated over $70 million in 2025 sales.

Key Facts

  • FDA approved Kamada's new in-house RFFIT laboratory for rabies virus neutralization testing.
  • The lab is located at Kamada's Beit Kama, Israel plant and is one of a limited number worldwide capable of such tests.
  • The lab was also approved by Health Canada and the Israeli Ministry of Health prior to FDA approval.
  • In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million.
  • The lab supports manufacturing of KEDRAB and KAMRAB from plasma collection to final product release.

Financial Impact

Operational efficiency gains on a franchise generating over $70 million in annual sales; no specific cost savings or revenue impact quantified.

operational efficiencycost of goods sold

Risk Factors

  • No quantified financial impact from the lab approval; benefits may be gradual.
  • Operational execution risk in transitioning testing from external to in-house capabilities.
  • Geopolitical risk from the lab's location in Israel.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-063140
Document: ea0292886-6k_kamada.htm0001213900-26-063140
Document: 0001213900-26-063140-index-headers.html0001213900-26-063140
Document: 0001213900-26-063140-index.html0001213900-26-063140
Document: 0001213900-26-063140.txt0001213900-26-063140

Track record

25 reports on KMDA

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026